Werewolf Files Full Merger Agreement with Ambros: $500M Reverse Merger, $150M PIPE, and CVR for Legacy Assets
HOWL has more than doubled off its 52-week low of $0.27 on elevated volume (38× avg).
Summary
Werewolf Therapeutics filed the full merger agreement for its reverse merger with Ambros Therapeutics, including a $150M PIPE, CVRs for legacy assets, and detailed ownership terms.
Key Events · M&A and Partnerships · HOWL
-
Reverse Merger with Ambros
Werewolf will merge with Ambros Therapeutics in an all-stock transaction valuing Ambros at $500M and Werewolf at $47.5M. Post-merger ownership: Ambros holders 71.7%, PIPE investors 21.5%, Werewolf holders 6.8%.
-
$150M Concurrent PIPE
A $150M private placement from healthcare investors, including RA Capital and Janus Henderson, will close immediately before the merger. Investors receive common stock and pre-funded warrants with a $0.001 exercise price.
-
Contingent Value Rights
Werewolf stockholders will receive one CVR per share, entitling them to payments from any future monetization of legacy assets WTX-124 and WTX-330.
-
Reverse Stock Split Planned
The merger agreement includes a reverse stock split to maintain Nasdaq listing compliance, with the ratio to be mutually agreed upon.
Analysis · HOWL · Life Sciences
This 425 filing provides the complete, legally binding terms of the reverse merger announced earlier today. Werewolf stockholders will own only 6.8% of the combined company, with Ambros holders at 71.7% and PIPE investors at 21.5%. The deal includes a $150M concurrent private placement, contingent value rights for Werewolf's legacy assets, and a reverse stock split. For a company with a going concern warning and $22M in cash, this transaction is transformative — it brings in $150M in new capital and shifts control to Ambros's management team. The filing also reveals termination fees, support agreements, and lock-up provisions that were not in the earlier summary.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 44.5% of the 301 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HOWL was trading at $1.04 on NASDAQ in the Life Sciences sector. The 52-week trading range was $0.27 to $2.38. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.